Publications by authors named "H T Schlamm"

Article Synopsis
  • - Fosmanogepix is a new antifungal medication targeting Gwt1 enzyme, effective against various fungal infections, including drug-resistant ones, available for both IV and oral use.
  • - A study evaluated its safety and efficacy in treating candidaemia in adults without neutropenia, administering fosmanogepix for 14 days and measuring treatment success through blood culture clearance and survival rates.
  • - The results showed an 80% treatment success rate with good tolerance and no serious side effects, indicating fosmanogepix's potential as a safe and effective option for treating candidaemia.
View Article and Find Full Text PDF

Invasive Fusarium infections cause high mortality. Fosmanogepix, a first-in-class antifungal agent, has potent activity against Fusarium. A patient with acute leukemia with invasive fusariosis, probably involving the central nervous system and caused by Fusarium lactis resistant to currently available antifungal agents, was cured of her infection with fosmanogepix.

View Article and Find Full Text PDF

Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non- albicans Candida species.

Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials.gov).

View Article and Find Full Text PDF

Background: Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.

View Article and Find Full Text PDF